<p>瑞士銀行（Bank Julius Baer  Co. Ltd Zurich）在最近向美國證券交易委員會提交的 13F 表格中表示，在第四季度將其在瑞思邁公司（ResMed Inc.，NYSE:RMD - 免費報告）的持股減少了 17.9%。該基金在季度內出售了 5,422 股後，持有瑞思邁的股票共 24,847 股。截至其最近的 SEC 文件，瑞思邁的持股價值為 6,031,000 美元。</p>
<ul>
<li>HCA Healthcare 上漲：減肥藥真的構成重大威脅嗎？</li>
</ul>
<p>其他一些機構投資者和對沖基金最近也調整了對 RMD 的持股。國際資產投資管理公司（International Assets Investment Management LLC）在第四季度購買了瑞思邁的新股份，價值約 25,000 美元。ORG Partners LLC 在第四季度將其在瑞思邁的持股增加了 181.6%。ORG Partners LLC 現在擁有 107 股瑞思邁的股票，價值 26,000 美元，此前在此期間又購買了 69 股。Imprint Wealth LLC 在第三季度購買了瑞思邁的新股份，價值約 26,000 美元。聖地亞哥的 WFA LLC 在第二季度購買了瑞思邁的新股份，價值約 26,000 美元。最後，Sunbelt Securities Inc.在第三季度購買了瑞思邁的新股份，價值 31,000 美元。54.98% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>瑞思邁股票上漲 0.1%</h2>
<p>週五，NYSE:RMD 的開盤價為 202.55 美元。瑞思邁公司的一年最低價為 198.61 美元，一年最高價為 293.81 美元。該公司的 50 日移動平均價格為 225.07 美元，200 日移動平均價格為 242.81 美元。公司的市值為 295.1 億美元，市盈率為 19.53，市盈增長比率為 1.29，貝塔值為 0.84。公司的債務與股本比率為 0.06，流動比率為 3.01，速動比率為 2.33。</p>
<p>瑞思邁（NYSE:RMD - 獲取免費報告）最近於 4 月 30 日發佈了季度財報。該醫療設備提供商報告季度每股收益（EPS）為 2.86 美元，超出分析師一致預期的 2.79 美元，超出幅度為 0.07 美元。瑞思邁的股本回報率為 25.35%，淨利潤率為 27.44%。該公司季度收入為 14.3 億美元，而分析師預期為 14.2 億美元。在去年同期，該公司每股收益為 2.37 美元。與去年同期相比，該季度的收入增長了 10.8%。平均而言，股票分析師預測瑞思邁在當前財政年度的每股收益將達到 11.13 美元。</p>
<h2>瑞思邁分紅公告</h2>
<p>該公司最近宣佈了季度分紅，將於 6 月 18 日支付。5 月 14 日的股東將獲得每股 0.60 美元的分紅。除息日為 5 月 14 日。這相當於每年 2.40 美元的分紅，分紅收益率為 1.2%。瑞思邁的分紅支付比率目前為 23.14%。</p>
<h2>分析師評級變動</h2>
<p>一些研究分析師最近對 RMD 股票發表了評論。KeyCorp 在 4 月 27 日的研究報告中將瑞思邁的目標價從 302.00 美元下調至 290.00 美元，並對該股票給予 “增持” 評級。富國銀行（Wells Fargo  Company）在 5 月 1 日的研究報告中將瑞思邁的目標價從 270.00 美元下調至 227.00 美元，並對該股票給予 “持平” 評級。摩根大通（JPMorgan Chase  Co.）在 4 月 15 日的研究報告中開始覆蓋瑞思邁的股票，並給予該公司 “增持” 評級。Piper Sandler 在 1 月 30 日的研究報告中將瑞思邁的目標價從 270.00 美元上調至 275.00 美元，並給予該公司 “中性” 評級。最後，花旗集團（Citigroup）在 4 月 9 日的研究報告中將瑞思邁的目標價從 345.00 美元下調至 340.00 美元，並對該公司給予 “買入” 評級。一位分析師對該股票給予 “強烈買入” 評級，九位給予 “買入” 評級，五位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 286.18 美元。</p>
<p><strong>閲讀我們關於 RMD 的最新研究報告</strong></p>
<h2>內部買賣</h2>
<p>在其他瑞思邁的新聞中，董事彼得·C·法雷爾（Peter C. Farrell）在 4 月 1 日的交易中出售了 2,000 股瑞思邁股票。該股票以平均 225.00 美元的價格出售，總價值為 450,000.00 美元。該交易在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，首席執行官邁克爾·J·法雷爾（Michael J. Farrell）在 3 月 9 日的交易中出售了 4,991 股公司的股票。該股票以平均 251.03 美元的價格出售，總價值為 1,252,890.73 美元。交易完成後，首席執行官持有公司 466,223 股股票，價值 117,035,959.69 美元。這代表其持股減少了 1.06%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士出售了價值 4,386,031 美元的 18,973 股公司股票。0.65% 的股票由公司內部人士持有。</p>
<h2>瑞思邁公司簡介</h2>
<p>（免費報告）</p>
<p>瑞思邁（ResMed）NYSE: RMD 是一家全球醫療設備和雲連接公司，專注於改善患有睡眠呼吸障礙和慢性呼吸疾病的人的治療效果。公司成立於 1989 年，總部位於加利福尼亞州聖地亞哥，開發、製造和分銷一系列設備和軟件，供全球患者、臨牀醫生和提供者使用。</p>
<p>瑞思邁的產品組合集中在非侵入性通氣和睡眠治療設備上，包括持續氣道正壓（CPAP）和雙水平設備、面罩及相關配件，用於治療阻塞性睡眠呼吸暫停和其他呼吸疾病。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過瑞思邁</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度財報後的對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇是其中之一</li>
</ul>
<p><strong>想知道其他對瑞思邁持有股份的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取瑞思邁公司（NYSE:RMD - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資瑞思邁 1,000 美元嗎？</h2>
<p>在考慮瑞思邁之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而瑞思邁並不在名單上。</p>
<p>雖然瑞思邁目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

瑞思邁

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>瑞士銀行瑞士寶銀行（Bank Julius Baer & Co. Ltd Zurich）在第四季度將其在瑞思邁（ResMed Inc.）的持股減少了 17.9%，目前持有 24,847 股，市值為 6,031,000 美元。其他機構投資者也調整了他們的持倉。瑞思邁的股票開盤價為 202.55 美元，市值為 295.1 億美元。該公司報告的季度每股收益（EPS）為 2.86 美元，超出預期，並宣佈每股派息 0.60 美元。分析師對該股票的評級意見不一，普遍評級為 “適度買入”，平均目標價為 286.18 美元</p>

<p>Bank Julius Baer &amp; Co. Ltd Zurich cut its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,847 shares of the medical equipment provider's stock after selling 5,422 shares during the quarter. Bank Julius Baer &amp; Co. Ltd Zurich's holdings in ResMed were worth $6,031,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>瑞士銀行（Bank Julius Baer  Co. Ltd Zurich）在最近向美國證券交易委員會提交的 13F 表格中表示，在第四季度將其在瑞思邁公司（ResMed Inc.，NYSE:RMD - 免費報告）的持股減少了 17.9%。該基金在季度內出售了 5,422 股後，持有瑞思邁的股票共 24,847 股。截至其最近的 SEC 文件，瑞思邁的持股價值為 6,031,000 美元。</p>
</div><ul>
<li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li>
</ul>
<div class="lb-trans"><ul>
<li>HCA Healthcare 上漲：減肥藥真的構成重大威脅嗎？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of RMD. International Assets Investment Management LLC purchased a new position in shares of ResMed in the fourth quarter worth about $25,000. ORG Partners LLC increased its holdings in shares of ResMed by 181.6% in the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 69 shares during the period. Imprint Wealth LLC bought a new stake in shares of ResMed during the 3rd quarter valued at about $26,000. WFA of San Diego LLC purchased a new position in ResMed in the 2nd quarter worth approximately $26,000. Finally, Sunbelt Securities Inc. purchased a new stake in shares of ResMed during the 3rd quarter valued at $31,000. 54.98% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些機構投資者和對沖基金最近也調整了對 RMD 的持股。國際資產投資管理公司（International Assets Investment Management LLC）在第四季度購買了瑞思邁的新股份，價值約 25,000 美元。ORG Partners LLC 在第四季度將其在瑞思邁的持股增加了 181.6%。ORG Partners LLC 現在擁有 107 股瑞思邁的股票，價值 26,000 美元，此前在此期間又購買了 69 股。Imprint Wealth LLC 在第三季度購買了瑞思邁的新股份，價值約 26,000 美元。聖地亞哥的 WFA LLC 在第二季度購買了瑞思邁的新股份，價值約 26,000 美元。最後，Sunbelt Securities Inc.在第三季度購買了瑞思邁的新股份，價值 31,000 美元。54.98% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>ResMed Stock Up 0.1%</h2>
<div class="lb-trans"><h2>瑞思邁股票上漲 0.1%</h2>
</div><p>NYSE:RMD opened at $202.55 on Friday. ResMed Inc. has a 1-year low of $198.61 and a 1-year high of $293.81. The firm's 50-day moving average price is $225.07 and its 200-day moving average price is $242.81. The company has a market capitalization of $29.51 billion, a PE ratio of 19.53, a P/E/G ratio of 1.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33.</p>
<div class="lb-trans"><p>週五，NYSE:RMD 的開盤價為 202.55 美元。瑞思邁公司的一年最低價為 198.61 美元，一年最高價為 293.81 美元。該公司的 50 日移動平均價格為 225.07 美元，200 日移動平均價格為 242.81 美元。公司的市值為 295.1 億美元，市盈率為 19.53，市盈增長比率為 1.29，貝塔值為 0.84。公司的債務與股本比率為 0.06，流動比率為 3.01，速動比率為 2.33。</p>
</div><p>ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $1.42 billion. During the same period in the previous year, the firm posted $2.37 EPS. The business's revenue for the quarter was up 10.8% compared to the same quarter last year. On average, equities analysts predict that ResMed Inc. will post 11.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>瑞思邁（NYSE:RMD - 獲取免費報告）最近於 4 月 30 日發佈了季度財報。該醫療設備提供商報告季度每股收益（EPS）為 2.86 美元，超出分析師一致預期的 2.79 美元，超出幅度為 0.07 美元。瑞思邁的股本回報率為 25.35%，淨利潤率為 27.44%。該公司季度收入為 14.3 億美元，而分析師預期為 14.2 億美元。在去年同期，該公司每股收益為 2.37 美元。與去年同期相比，該季度的收入增長了 10.8%。平均而言，股票分析師預測瑞思邁在當前財政年度的每股收益將達到 11.13 美元。</p>
</div><h2>ResMed Dividend Announcement</h2>
<div class="lb-trans"><h2>瑞思邁分紅公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed's dividend payout ratio is presently 23.14%.</p>
<div class="lb-trans"><p>該公司最近宣佈了季度分紅，將於 6 月 18 日支付。5 月 14 日的股東將獲得每股 0.60 美元的分紅。除息日為 5 月 14 日。這相當於每年 2.40 美元的分紅，分紅收益率為 1.2%。瑞思邁的分紅支付比率目前為 23.14%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of research analysts recently commented on RMD shares. KeyCorp reduced their target price on ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, April 27th. Wells Fargo &amp; Company decreased their price target on shares of ResMed from $270.00 to $227.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, May 1st. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Piper Sandler raised their price objective on ResMed from $270.00 to $275.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, January 30th. Finally, Citigroup lowered their target price on ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p>
<div class="lb-trans"><p>一些研究分析師最近對 RMD 股票發表了評論。KeyCorp 在 4 月 27 日的研究報告中將瑞思邁的目標價從 302.00 美元下調至 290.00 美元，並對該股票給予 “增持” 評級。富國銀行（Wells Fargo  Company）在 5 月 1 日的研究報告中將瑞思邁的目標價從 270.00 美元下調至 227.00 美元，並對該股票給予 “持平” 評級。摩根大通（JPMorgan Chase  Co.）在 4 月 15 日的研究報告中開始覆蓋瑞思邁的股票，並給予該公司 “增持” 評級。Piper Sandler 在 1 月 30 日的研究報告中將瑞思邁的目標價從 270.00 美元上調至 275.00 美元，並給予該公司 “中性” 評級。最後，花旗集團（Citigroup）在 4 月 9 日的研究報告中將瑞思邁的目標價從 345.00 美元下調至 340.00 美元，並對該公司給予 “買入” 評級。一位分析師對該股票給予 “強烈買入” 評級，九位給予 “買入” 評級，五位給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 286.18 美元。</p>
</div><p><strong>Read Our Latest Research Report on RMD</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 RMD 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $251.03, for a total value of $1,252,890.73. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $117,035,959.69. This represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 18,973 shares of company stock valued at $4,386,031. 0.65% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他瑞思邁的新聞中，董事彼得·C·法雷爾（Peter C. Farrell）在 4 月 1 日的交易中出售了 2,000 股瑞思邁股票。該股票以平均 225.00 美元的價格出售，總價值為 450,000.00 美元。該交易在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，首席執行官邁克爾·J·法雷爾（Michael J. Farrell）在 3 月 9 日的交易中出售了 4,991 股公司的股票。該股票以平均 251.03 美元的價格出售，總價值為 1,252,890.73 美元。交易完成後，首席執行官持有公司 466,223 股股票，價值 117,035,959.69 美元。這代表其持股減少了 1.06%。該銷售的 SEC 文件提供了更多信息。在過去 90 天內，內部人士出售了價值 4,386,031 美元的 18,973 股公司股票。0.65% 的股票由公司內部人士持有。</p>
</div><h2>ResMed Profile</h2>
<div class="lb-trans"><h2>瑞思邁公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.</p>
<div class="lb-trans"><p>瑞思邁（ResMed）NYSE: RMD 是一家全球醫療設備和雲連接公司，專注於改善患有睡眠呼吸障礙和慢性呼吸疾病的人的治療效果。公司成立於 1989 年，總部位於加利福尼亞州聖地亞哥，開發、製造和分銷一系列設備和軟件，供全球患者、臨牀醫生和提供者使用。</p>
</div><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p>
<div class="lb-trans"><p>瑞思邁的產品組合集中在非侵入性通氣和睡眠治療設備上，包括持續氣道正壓（CPAP）和雙水平設備、面罩及相關配件，用於治療阻塞性睡眠呼吸暫停和其他呼吸疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than ResMed</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過瑞思邁</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先的量子公司在第一季度財報後的對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇是其中之一</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RMD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對瑞思邁持有股份的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取瑞思邁公司（NYSE:RMD - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ResMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資瑞思邁 1,000 美元嗎？</h2>
</div><p>Before you consider ResMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮瑞思邁之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而瑞思邁並不在名單上。</p>
</div><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然瑞思邁目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD

Market Beat

HCA控股

科凱國際

富國銀行

摩根大通

Piper Sandler Cos

花旗

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

蘇黎世的瑞士寶盛銀行有限公司減少了其在瑞思邁公司 $RMD 的股票持倉